These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 12202891)

  • 21. Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India.
    Okonkwo QL; Draisma G; der Kinderen A; Brown ML; de Koning HJ
    J Natl Cancer Inst; 2008 Sep; 100(18):1290-300. PubMed ID: 18780864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost analysis of the National Breast and Cervical Cancer Early Detection Program: selected states, 2003 to 2004.
    Ekwueme DU; Gardner JG; Subramanian S; Tangka FK; Bapat B; Richardson LC
    Cancer; 2008 Feb; 112(3):626-35. PubMed ID: 18157831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mammography screening: A major issue in medicine.
    Autier P; Boniol M
    Eur J Cancer; 2018 Feb; 90():34-62. PubMed ID: 29272783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The relevance of unrelated costs internal and external to the healthcare sector to the outcome of a cost-comparison analysis of secondary prevention: the case of general colorectal cancer screening in the German population.
    Tscheulin DK; Drevs F
    Eur J Health Econ; 2010 Apr; 11(2):141-50. PubMed ID: 19449159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Developing and testing a cost-assessment tool for cancer screening programs.
    Subramanian S; Ekwueme DU; Gardner JG; Trogdon J
    Am J Prev Med; 2009 Sep; 37(3):242-7. PubMed ID: 19666160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Surveillance and cost-effectiveness of colonoscopy in asymptomatic increased risk subjects of colorectal cancer: Ferrara experience].
    Matarese V; Pezzoli A; Trevisani L; Boccia S; Brancaleoni M; Simone L; Feo C; Gullini S
    Recenti Prog Med; 2004; 95(7-8):352-7. PubMed ID: 15303544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modeling cost-effectiveness of cervical cancer screening in Hungary.
    Vokó Z; Nagyjánosi L; Margitai B; Kövi R; Tóth Z; László D; Kaló Z
    Value Health; 2012 Jan; 15(1):39-45. PubMed ID: 22264970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preventing cancer: using health dollars wisely.
    Wasserman S
    NCSL Legisbrief; 2004 Feb; 12(8):1-2. PubMed ID: 14974484
    [No Abstract]   [Full Text] [Related]  

  • 29. Cost-effectiveness of cervical-cancer screening in five developing countries.
    Goldie SJ; Gaffikin L; Goldhaber-Fiebert JD; Gordillo-Tobar A; Levin C; Mahé C; Wright TC;
    N Engl J Med; 2005 Nov; 353(20):2158-68. PubMed ID: 16291985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Program-specific cost-effectiveness analysis: breast cancer screening policies for a safety-net program.
    Melnikow J; Tancredi DJ; Yang Z; Ritley D; Jiang Y; Slee C; Popova S; Rylett P; Knutson K; Smalley S
    Value Health; 2013; 16(6):932-41. PubMed ID: 24041343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cost-effectiveness evaluation of predictive molecular diagnostics using the example of hereditary non-polyposis colorectal cancer (HNPCC)].
    Hagen A; Hessabi HK; Gorenoi V; Schönermark MP
    Gesundheitswesen; 2008 Jan; 70(1):18-27. PubMed ID: 18273760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer screening uptake: association with individual characteristics, geographic distribution, and time trends in Italy.
    Carrozzi G; Sampaolo L; Bolognesi L; Sardonini L; Bertozzi N; Giorgi Rossi P; Zappa M; Baldissera S; Campostrini S; Ferrante G; Masocco M; Minardi V; D'Argenzio A; Moghadam PF; Quarchioni E; Ramigni M; Trinito MO; Salmaso S;
    Epidemiol Prev; 2015; 39(3 Suppl 1):9-18. PubMed ID: 26405772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Age group specific gap between treatment cost of and mortality due to breast and colorectal cancer.
    Boncz I; Sebestyén A; Pintér I; Betlehem J; Kriszbacher I; Csere T; Mangel L; Bódis J
    J Clin Oncol; 2007 Oct; 25(28):4501-2; author reply 4502-3. PubMed ID: 17906215
    [No Abstract]   [Full Text] [Related]  

  • 34. Cost-effectiveness of mammography screening for breast cancer in a low socioeconomic group of Iranian women.
    Barfar E; Rashidian A; Hosseini H; Nosratnejad S; Barooti E; Zendehdel K
    Arch Iran Med; 2014 Apr; 17(4):241-5. PubMed ID: 24724599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of the Norwegian breast cancer screening program.
    van Luijt PA; Heijnsdijk EA; de Koning HJ
    Int J Cancer; 2017 Feb; 140(4):833-840. PubMed ID: 27861849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia.
    Tsoi KK; Ng SS; Leung MC; Sung JJ
    Aliment Pharmacol Ther; 2008 Aug; 28(3):353-63. PubMed ID: 18638075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries.
    Wu GH; Wang YM; Yen AM; Wong JM; Lai HC; Warwick J; Chen TH
    BMC Cancer; 2006 May; 6():136. PubMed ID: 16723013
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes and cost evaluation of the first two rounds of a colorectal cancer screening program based on immunochemical fecal occult blood test in northern Italy.
    Parente F; Boemo C; Ardizzoia A; Costa M; Carzaniga P; Ilardo A; Moretti R; Cremaschini M; Parente EM; Pirola ME
    Endoscopy; 2013; 45(1):27-34. PubMed ID: 23254404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness modeling of colorectal cancer: computed tomography colonography vs colonoscopy or fecal occult blood tests.
    Lucidarme O; Cadi M; Berger G; Taieb J; Poynard T; Grenier P; Beresniak A
    Eur J Radiol; 2012 Jul; 81(7):1413-9. PubMed ID: 21444171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing.
    Wong CK; Lam CL; Wan YF; Fong DY
    BMC Cancer; 2015 Oct; 15():705. PubMed ID: 26471036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.